Identification of noradrenergic nerve terminals immunoreactive for neuropeptide Y and vasoactive intestinal peptide in the rat kidney

Knight, David S.; Fabre, Renaud; Beal, John A.

doi:10.1002/aja.1001840303

Cited by 30 publications

(7 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…*, p < 0.05, one-way variance analysis versus respective controls; †, p < 0.05, one-way variance analysis, AngII versus AngII + Bos. D Casellas et al 433 "hidden" among tubules and only limited lengths of the vascular neural plexus have been studied via serial or thick tissue sections (2)(3)(4)18,23,27). The method we devised is complementary to traditional histology, and provides an integrated view of the neural plexus along renal preglomerular vessels.…”

Section: Discussionmentioning

confidence: 99%

New Method for Imaging Innervation of the Renal Preglomerular Vasculature. Alterations in Hypertensive Rats

et al. 2000

View full text Add to dashboard Cite

Objective: To develop a new method for viewing adrenergic innervation along renal preglomerular vessels; to assess nerve densities and vascular lesions along arcuate arteries (ArcA), arcuate arterial branches (ArcB), and interlobular arteries (ILA) in spontaneously hypertensive rats (SHR) and in angiotensin II (AngII) and in N G -nitro-L-arginine methyl ester (L-NAME) hypertensive rats. Methods: Preglomerular vasculatures were isolated after HCl maceration and were immunostained against synaptophysin, a membrane protein of synaptic vesicles. Lesions were stained with Sudan black. Longitudinal nerve densities and relative frequencies of ArcA, ArcB, and ILA endowed with sudanophilic lesions were assessed separately. Results: Synaptophysin immunostaining revealed the vascular neural plexus. Nerves were adrenergic, as the plexus was destroyed by treatment with 6-hydroxy dopamine. Vascular lesions were not seen in SHR, and increased nerve density was observed along ArcA and ILA. In L-NAME-and AngIIhypertensive rats, vascular lesions affected predominantly ArcB and ILA, and nerve density was reduced by 12% and 28% (ArcA), 37% and 31% (ArcB), and by 55% and 34% (ILA), respectively, versus normotensive controls. Endothelin-1 receptor blockade did not affect AngII-induced hypertension but prevented both lesion development and reduction of density of the vascular neural plexus. Conclusions: The method we have devised provides a direct en face view of the vascular adrenergic innervation of isolated preglomerular vasculature. Measurements in hypertensive rat models suggest a link between vascular lesions and reduction in nerve density in hypertension. Endothelin-1 likely plays a key role in mediating both vascular injury and altered vascular nerve density in hypertension. Microcirculation (2000) 7, 429-437.

show abstract

Section: Discussionmentioning

confidence: 99%

New Method for Imaging Innervation of the Renal Preglomerular Vasculature. Alterations in Hypertensive Rats

et al. 2000

View full text Add to dashboard Cite

show abstract

“…NPY is found in almost all renal sympathetic neurons [27,56]. Accordingly, the intrarenal NPY content decreases dramatically upon destruction of sympathetic nerve terminals by 6-hydroxy-dopamine [9].…”

Section: Presence and Release Of Npy In The Kidneymentioning

confidence: 99%

“…Immunohistochemical techniques detect NPY in the kidney of various species including rat [9,27,56,98], mouse [9], hamster [9], guinea pig [9,98], pig [98], dog [98], monkey [9,82] and man [9,51,82]. NPY is found in almost all renal sympathetic neurons [27,56].…”

Section: Presence and Release Of Npy In The Kidneymentioning

confidence: 99%

Renal effects of neuropeptide Y

Bischoff¹,

Michel²

1998

Pfl�gers Archiv European Journal of Physiology

View full text Add to dashboard Cite

Neuropeptide Y (NPY) is a co-transmitter of the sympathetic nervous system including the renal nerves. The kidney expresses NPY receptors, which can also be activated by peptide YY (PYY), a circulating hormone released from gastrointestinal cells. Five subtypes of NPY receptors have been cloned, among which Y1, Y2 and Y5 appear to be involved in the regulation of renal function. NPY produces potent renal vasoconstriction in vitro in isolated interlobar arteries and in the isolated perfused kidney and in vivo upon intrarenal or systemic administration via a Y1 receptor. Nevertheless glomerular filtration rate is altered only little if at all by NPY, indicating a greater effect on the vas efferens than the vas afferens. NPY can inhibit renin release via Y1-like receptors. NPY can stimulate Na+/K+ adenosine triphosphatase (Na+/K+-ATPase) in proximal tubules via Y2 receptors and can antagonize the effects of vasopressin on isolated collecting ducts. It can also act prejunctionally to inhibit noradrenaline release via Y2 receptors. Despite the profound reductions of renal blood flow, systemic NPY infusion can cause diuresis and natriuresis; this is largely independent of pressure natriuresis mechanisms and is possibly mediated by an extrarenal Y5 receptor. Studies with the converting enzyme inhibitor ramiprilat and the bradykinin receptor antagonist icatibant indicate that bradykinin mediates, at least partly, diuretic NPY effects. NPY antagonists enhance basal renal blood flow but do not alter basal diuresis or natriuresis indicating that renovascular, but not tubular, NPY receptors may be tonically activated by endogenous NPY.

show abstract

“…Peptides, including neuropeptide Y (NPY), neurotensin, vasoactive intestinal polypeptide, calcitonin gene-related peptide (CGRP), substance P, somatostatin and, to a lesser degree, enkephalin (H6kfelt et al, 1978;Mattiasson, 1985;Suet al, 1986;Reinecke & Forssmann, 1988;Knight et al, 1989), have also been observed in nerves innervating the urinary tract. A consistent observation has been that there is a wealth of CGRP-containing sensory nerves supplying the rat urinogenital system (Ghatei et al, 1985;Inyama et al, 1986;Su et al, 1986).…”

Section: Introductionmentioning

confidence: 99%

Sympathetic and sensory innervation of the urinary tract in young adult and aged rats: a semi-quantitative histochemical and immunohistochemical study

Warburton

Santer

1994

Histochem J

View full text Add to dashboard Cite

The sympathetic innervation of the urinary tract of young adult (4 months) and aged (24+ months) rats has been examined by glyoxylic acid-induced fluorescence for the detection of noradrenaline and by immunofluorescence using antisera against tyrosine hydroxylase (TH) and neuropeptide Y (NPY). Immunostaining for calcitonin gene-related peptide (CGRP), known to be present in pelvic sensory nerves, was also performed. Semi-quantitative estimations of nerve densities were made of noradrenergic and peptidergic fibres innervating the smooth musculature of the ureter, bladder and urethra, and of the urinary tract vasculature. In the aged rats the overall patterns of innervation remained unchanged. However, with the exception of the vesical vasculature, the density of noradrenergic innervation decreased as did the intensity of histofluorescence. A similar pattern of results was observed by TH and NPY immunofluorescence. The results present evidence for a diminution in the sympathetic control of the urinary tract in aged rats. The pattern and density of CGRP-immunoreactive nerves was unchanged in the aged animals suggesting that pelvic visceral sensory innervation is more resistant to the effects of advancing age.

show abstract

Identification of noradrenergic nerve terminals immunoreactive for neuropeptide Y and vasoactive intestinal peptide in the rat kidney

Cited by 30 publications

References 56 publications

New Method for Imaging Innervation of the Renal Preglomerular Vasculature. Alterations in Hypertensive Rats

New Method for Imaging Innervation of the Renal Preglomerular Vasculature. Alterations in Hypertensive Rats

Renal effects of neuropeptide Y

Sympathetic and sensory innervation of the urinary tract in young adult and aged rats: a semi-quantitative histochemical and immunohistochemical study

Contact Info

Product

Resources

About